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Abstract 
 
Background 
Several recent studies have provided evidence that polymorphisms in the telomerase reverse 
transcriptase (TERT) gene sequence are associated with cancer development, but a comprehensive 
synopsis is not available. We conducted a systematic review and meta-analysis of the available 
molecular epidemiology data regarding the association between TERT locus polymorphisms and 
predisposition to cancer.  
 
Methods 
A systematic review of the English literature was conducted by searching PubMed, Embase, 
Cancerlit, Google Scholar, and ISI Web of Knowledge databases for studies on associations 
between TERT locus polymorphisms and cancer risk. Random-effects meta-analysis was performed 
to pool per-allele odds ratios for TERT locus polymorphisms and risk of cancer, and between-study 
heterogeneity and potential bias sources (eg, publication and chasing bias) were assessed. Because 
the TERT locus includes the cleft lip and palate transmembrane 1-like (CLPTM1L) gene, which is in 
linkage disequilibrium with TERT, CLPTM1L polymorphisms were also analyzed. Cumulative 
evidence for polymorphisms with statistically significant associations was graded as “strong,” 
“moderate,” and “weak,” according to the Venice criteria. The joint population attributable risk 
(PAR) was calculated for polymorphisms with strong evidence of association. 
 
Results 
Eighty-five studies enrolling 490,901 subjects and reporting on 494 allelic contrasts were retrieved. 
Data were available on 67 TERT locus polymorphisms and 24 tumor types, for a total of 221 unique 
combinations of polymorphisms and cancer types. Upon meta-analysis, a statistically significant 
association with the risk of any cancer type was found for 22 polymorphisms. Strong, moderate, and 
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weak cumulative evidence for association with at least one tumor type was demonstrated for 11, 9, 
and 14 polymorphisms, respectively. For lung cancer, which was the most studied tumor type, the 
estimated joint PAR for three polymorphisms (TERT rs2736100, intergenic rs4635969, and 
CLPTM1L rs402710) was 41%. Strong evidence for lack of association was identified for five 
polymorphisms in three tumor types. 
 
Conclusions 
To our knowledge, this is the largest collection of data for associations between TERT locus 
polymorphisms and cancer risk. Our findings support the hypothesis that genetic variability in this 
genomic region can modulate cancer susceptibility in humans.  
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Introduction 
Human telomeres consist of repetitive TTAGGG DNA sequences that associate with a series of 
telomere binding proteins (shelterin complex) believed to provide genomic stability by protecting 
the linear chromosome ends from being recognized as DNA breaks to be repaired (1,2). The 
inability of the DNA replication machinery to copy the extreme ends of chromosomes, often 
referred to as the "end replication problem," is consistent with the observation that cells can lose 
telomeric repeats without initially affecting cell function (2). Thus, most human somatic cells show 
progressive telomere shortening with ongoing cell division until a subset of telomeres reach a 
critically shortened length and induce a DNA damage signal triggering a tumor protein p53 (TP53)-
dependent G1/S cell cycle arrest referred to as replicative senescence. Thus, telomeres not only 
serve as chromosome "caps" to protect chromosome ends from being recognized as DNA damage, 
but also serve as a gauge for the mitotic (replication) age of a cell (1,2).  
The gene encoding the enzyme telomerase reverse transcriptase (TERT), which synthesizes the 
TTAGGG DNA sequences onto the ends of chromosomes in cooperation with other proteins of the 
core telomerase complex (eg, telomerase RNA component [TERC] and dyskerin [DKC1]), is 
located on chromosome 5 (locus 5p15.33). With its activity, telomerase helps maintain the integrity 
of the genome in embryonic stem cells and in proliferating progenitor cells derived from quiescent 
normal stem cells (3,4). Telomerase is silent in the vast majority of human tissues and is only 
expressed in a small number of normal cell types such as dividing male germ-line spermatocytes 
and a subset of proliferating somatic adult stem cells (4). 
In the early 1990s, investigators proposed a connection between telomeres, telomerase, aging, and 
cancer (5,6). The hypothesis was that most normal human cells lack telomerase activity and their 
telomeres shorten with each cell division, until they enter replicative senescence. Cells that lose 
critical cell-cycle checkpoint functions escape this initial growth arrest (replicative senescence) and 
continue to divide; cells that bypass senescence eventually enter a second growth arrest state (crisis) 
when many shortened chromosome ends fuse, leading to chromosome bridge-breakage-fusion 
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cycles, which almost universally result in apoptosis (5). In human cells, these two mechanisms to 
restrict cell growth (replicative senescence and crisis) are potent anticancer protection mechanisms. 
Most human cells remain in this crisis period with cell growth being balanced by cell death until a 
rare cell acquires a mechanism, such as telomerase expression, that can maintain or lengthen 
telomeres. Cells that have escaped crisis generally have two defining hallmarks, telomere stability 
and reactivation of telomerase; this rare cell type that can maintain telomeres is then able to grow 
continuously (ie, becomes immortal), and this is generally believed to be a critical step in cancer 
progression (5).  
In the light of the already abundant evidence linking telomerase activity to the development of 
many tumor types, many researchers are devising a variety of methods to target telomerase as a 
novel therapeutic approach potentially useful in a range of cancers (7,8); moreover, other 
investigators are testing the hypothesis that variability of the TERT gene sequence might be a 
general mechanism affecting individual cancer predisposition (9). Regarding the latter field of 
investigation, tens of thousands of patients affected with different cancer histotypes have been so 
far enrolled in molecular epidemiology studies and some TERT polymorphisms have been reported 
to be associated with cancer risk, although findings are not always concordant (9). Because there is 
no synopsis available on this subject, we systematically reviewed the data published to date on the 
relationship between TERT locus polymorphisms and cancer risk, and quantitatively summarized 
the available evidence by performing a formal meta-analysis. 
 
 
Materials and Methods 
 
Search Strategy, Eligibility Criteria, and Data Extraction 
We followed the methods proposed by the Human Genome Epidemiology Network (HuGENet) 
(10) as well as the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
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(PRISMA) (11) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines 
(12). A two-step search strategy was adopted. First, a systematic review of original articles, reviews 
and meta-analyses analyzing the association between TERT locus polymorphisms and cancer risk 
was performed by searching PubMed, Embase, Cancerlit, Google Scholar, and ISI Web of 
Knowledge databases (Supplementary Figure 1, available online). The search included the 
following keywords: "cancer", "tumor", "carcinoma", "melanoma", "sarcoma", "lymphoma", 
"leukemia", "polymorphism", "SNP", "variant", "risk", "association", "TERT", "telomerase", 
"locus", "5p15.33" and "gene". The 5'-end of TERT resides in a 62 Kb region of high linkage 
disequilibrium (LD) that encompasses the upstream gene cleft lip and palate transmembrane 1-like 
(CLPTM1L)  (9) (Supplementary Figure 2, available online). Therefore, polymorphisms not 
belonging to the TERT gene but localizing within this LD area might be tagging relevant TERT 
polymorphisms; accordingly, CLPTM1L was used as an additional search term in the second step. 
Finally, in the light of the growing diffusion of high-throughput technological platforms for the 
investigation of gene polymorphisms, the expression "genome wide association study" and its 
acronym "GWAS" were also used as key words. In order to retrieve other potentially relevant data, 
we then performed the following: 1) the name or identity of each polymorphism was used as a 
keyword to further refine the search; 2) cited references from selected articles were reviewed; 3) 
publicly available databases dedicated to associations between genotype and phenotype (eg, 
Database of Genotypes and Phenotypes [dbGaP], http://www.ncbi.nlm.nih.gov/gap) were searched; 
4) authors were contacted whenever unreported data were potentially useful for the systematic 
review or to rule out overlapping data reported in different publications.  
Studies dealing with the association between any TERT locus polymorphism and 
predisposition to any type of cancer in humans were considered eligible, provided that the raw or 
summary data necessary to calculate the risks were available. Exclusion criteria were non-English 
language and data published in abstract form. For each polymorphism, exclusion criteria were less 
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than 5% minor allele frequency (MAF) in control subjects (rare polymorphisms) and violation of 
Hardy-Weinberg equilibrium (HWE).  
The following data were extracted from eligible studies: authors' names; region or country 
where the study was conducted; year of publication; number of case subjects with cancer and 
healthy control subjects; ethnicity; allelic frequency in both case subjects and control subjects (if no 
raw data were available, summary data were collected; ie, odds ratios [ORs] and 95% confidence 
intervals [CIs]); MAF and HWE in control subjects; study design, genotyping, and statistical 
methods.  For analysis purposes, the database, which will be updated on a yearly basis and will be 
publicly available on the Melanoma Molecular Map Project website [(13); http://www.mmmp.org], 
was frozen in April 2011. Data were extracted independently by the two investigators (DV and SM) 
in order to ensure homogeneity of data collection and to rule out the effect of subjectivity in data 
gathering and entry. Disagreements were resolved by iteration, discussion, and consensus. To 
unravel potential systematic biases, a third investigator (DN) performed a concordance study by 
independently reviewing all eligible studies; complete concordance (100%) was reached for all 
variables assessed. 
 
Statistical Analysis 
Meta-analysis. Because all the investigated gene variants were biallelic polymorphisms, per-allele 
odds ratios and corresponding 95% confidence intervals were used to assess the strength of 
association between each genetic variant and cancer risk, where protective and risk alleles were 
associated with ORs less than or greater than 1, respectively. Per-allele ORs were calculated for 
each study and each polymorphism, assuming a co-dominant genetic model. This assumption was 
suggested by the following reasons: 1) for some studies (including many GWAS), neither raw nor 
summary genotype data were available (only per-allele ORs were reported, which only allows to 
explore the co-dominant model); 2) the co-dominant model is widely used as a conservative choice 
between the recessive and dominant models, and 3) it does not require adjustment for multiple 
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hypotheses (which is necessary when different models are tested); 4) methods that let the data 
dictate the genetic model (ie, model-free approach) require raw data on genotype distributions 
(which were not available for many identified studies).  
For each allelic contrast (ie, data regarding a specific polymorphism and a given tumor type), 
summary per-allele ORs (meta-risks) were calculated by performing random-effects meta-analysis 
as per Der Simonian and Laird (ie, using the inverse variance method to weight the studies), a Z test 
being used to formally prove the statistical significance. The choice of the random-effects model 
was suggested by two main reasons: 1) the variety of histological cancer types, which was far from 
being fully represented for each genetic variant; 2) because the Q test for between-study 
heterogeneity is characterized by low statistical power, which is especially relevant when few 
studies are available; 3) in general, the random-effects model is a more conservative choice when 
heterogeneity is present, whereas it reduces to the fixed-effect model when heterogeneity is absent. 
For each polymorphism (whose allele of interest is indicated by the corresponding nucleotide letter 
in squared brackets), a meta-analysis was performed if at least two data sources were available. 
Stratification by ethnicity and histological subtype was done if data permitted. When a publication 
reported the data in an ancestry-specific way, each ancestral subset was considered as a distinct 
study. Similarly, with regard to GWAS, if data were available, discovery (hypothesis testing) and 
replication (validation) phases were considered as separate studies. 
Meta-analysis also included evaluation of between-study heterogeneity, sensitivity analysis, and 
examination for bias. Heterogeneity (true variance of effect size across studies) was formally 
investigated using a Q test (to assess whether observed variance exceeds expected variance) and I
2
 
statistic (it indicates the percentage of the variability in effect estimates because of  true 
heterogeneity rather than sampling error) (14). The Q test for heterogeneity was also used to 
formally compare effects (ie, meta-risk) between groups of interest (eg, different ethnicities). 
The extent to which the combined risk estimate might be affected by individual studies was 
assessed by consecutively omitting every study from the meta-analysis (leave-one-out sensitivity 
 10 
analysis). This approach would also capture the effect of the oldest or first positive study (first study 
effect). 
Funnel plot was used to detect the so-called "small study effect." Publication and selection biases in 
meta-analysis are more likely to affect small studies, which also tend to be of lower methodological 
quality (15). Funnel plot asymmetry was formally investigated with the Egger linear regression 
approach (Egger’s test) and the Begg rank correlation test (Begg’s test). The impact of small study 
effect bias on the summary effects was formally assessed by means of the trim-and-fill method 
described by Duval and Tweedie (16). The excess of statistically significant findings (potentially 
indicating the so-called "chasing bias") was evaluated by the test proposed by Ioannidis and 
Trikalinos (Ioannidis and Trikalinos test) (17).  
The population attributable risk (PAR) was calculated using the following formula:  
Pr (RR – 1) / [1 + Pr (RR – 1)], where Pr is the proportion of control subjects exposed to the allele 
of interest and the relative risk (RR) was estimated using the summary estimates (ORs) calculated 
by the meta-analysis. The joint PAR for combinations of polymorphisms was calculated as follows: 
1 – (∏1→n [1–PARi]), where PARi corresponds to the individual PAR of the ith polymorphism and n 
is the number of polymorphisms considered (18). Because PAR is a relative measure of effect and 
thus it does not account for the absolute risk of disease, we also calculated the attributable 
community risk (ACR), according to the following formula: (Ic – I0)/Ic, where Ic is the crude risk in 
the general population (probability of developing the disease during the entire lifetime) and I0 is the 
risk of disease in non-exposed (ie, in people carrying the protective allele) (19).  
P values less than .05 were considered statistically significant for all tests, except for Q test for 
heterogeneity, Egger's test, Begg's test and Ioannidis and Trikalinos test, for which a less stringent 
10% alpha level of statistical significance was applied. The latter three tests were performed if at 
least four studies were available. All tests were two-sided. The Bonferroni method was used for P 
value adjustment in case of multiple testing. Statistical analyses were performed with STATA 
11.0/SE software (College Station, TX, USA).  
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Assessment of cumulative evidence. In order to evaluate the epidemiological credibility of each 
statistically significant association identified by meta-analysis, we used the Venice criteria (10,20). 
Briefly, credibility was defined as “strong,” “moderate” or “weak” based on grades A, B or C in 
three categories: 1) amount of evidence, 2) replication of the association, and 3) protection from 
bias. Amount of evidence (which roughly depends upon the study sample size) was graded by the 
sum of test allele among case and control subjects in the meta-analysis: grades A, B or C were 
assigned for values greater than 1000, 100–1000 and less than 100, respectively. Replication was 
graded by the heterogeneity statistic: grades A, B, and C were assigned for I
2
 less than 25%, 25–
50%, and greater than 50%, respectively. Protection from bias was graded as grade A if there was 
no observable bias (bias was unlikely to explain the presence of the association), grade B if bias 
could be present, or grade C if bias was evident. Assessment of protection from bias also considered 
the magnitude of association: a grade “C” was assigned to an association with a summary OR less 
than 1.15, or greater than 0.85 in case of protective effect.  
Overall, the cumulative epidemiological evidence for statistically significant associations upon 
meta-analysis were considered to be “strong” if all three grades were A, “weak” if any grade was C, 
and “moderate” in all other cases. In case of no statistically significant association upon meta-
analysis, the minimum detectable risk was calculated considering a hypothetical study with sample 
size equal to the combined sample sizes of the studies reporting on a given polymorphism (error 
alpha and power were set at 5% and 90%, respectively). If no heterogeneity was found (I
2
 <25% 
and Q test P >.10) and the detectable alternative included non-negligible associations (ie, OR ≥1.15 
or ≤0.87), we considered the cumulative evidence sufficient to rule out any meaningful relationship 
between that polymorphism and cancer risk (strong evidence); in the other cases the evidence for 
lack of association was considered weak (ie, more data are necessary before the association can be 
ruled out). 
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Results 
Literature Search 
We found  6,497 potentially relevant articles, and retrieved 66 articles (18,21-84) reporting on 85 
case–control studies that assessed the association between TERT locus polymorphisms and cancer 
risk, and met the eligibility criteria (Supplementary Figure 1, available online). They were 
published in a relatively limited time span (2003–2011), witnessing the recent interest in this 
molecular epidemiology field. We identified 494 allelic contrasts after including ethnicity and 
tumor subtype specific data, whose details are reported in Supplementary Table 1, available online. 
Overall, data were available on 67 polymorphisms and 24 tumor types, with 490,901 subjects being 
genotyped (195,305 case subjects and 295,596 control subjects): the 221 unique combinations of 
TERT locus polymorphisms with cancer types are depicted in a heat-map (Supplementary Figure 3, 
available online), which also includes information on number of studies, type of association 
(statistically significant vs non-statistically significant), and the level of evidence (strong, moderate, 
and weak) for association. Considering the total number of case and control subjects enrolled in the 
eligible studies, TERT locus polymorphisms were most frequently investigated in lung cancer 
(56,682 subjects; 29.0%), the only tumor type for which data on histological subtypes could be 
included in the meta-analysis; the other five most frequently studied tumor types were prostate 
(47,294 subjects; 24.2%), colon (16,279 subjects; 8.3%), breast (15,090 subjects; 7.7%) and bladder 
(10,202 subjects; 5.2%) carcinomas, and central nervous system (CNS) tumors (8,795 subjects; 
4.5%). 
The median number of subjects enrolled per study was 2,771 (range: 125–79,600). White 
subjects of European ancestry was by far most frequently involved (425,010 subjects; 86.5%), 
Asian ethnicity representing virtually all the remaining subjects. In the majority of the studies (58 of 
85), selected TERT locus polymorphisms were investigated, whereas the remaining 27 were 
GWAS. All variants were single-nucleotide polymorphism (SNP), except for two minisatellite 
polymorphisms (TERT MNS16a and VNTR2-2nd) and one deletion (TERT Glu441del).  
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Among the 485 allelic contrasts for which an OR could be calculated, 233 (48%) showed a 
statistically significant association with risk of cancer (Supplementary Table 1, available online). 
Available data enabled us to perform 118 meta-analyses (including 41 subgroup analyses based on 
specific ancestries and histological subtypes) for 35 polymorphisms tested in one or more different 
tumor types and for which at least two studies were available. The main findings of these meta-
analyses reporting 75 (64%) statistically significant associations and 43 (36%) non-statistically 
significant associations between TERT locus polymorphisms and cancer, are shown in Table 1 and 
Table 2, respectively.  
Overall, 22 polymorphisms were associated with the risk of developing one or more types of 
cancer, but only 11 showed strong cumulative evidence according to the international guidelines 
known as Venice criteria (moderate and weak cumulative evidence was found for 9 and 14 
polymorphisms, respectively). In particular, among the 75 allelic contrasts for which the meta-
analysis showed statistically significant associations with cancer risk, the cumulative evidence was 
strong, moderate, and weak for 20 (27%), 15 (20%), and 40 (53%) allelic contrasts, respectively. 
The results for polymorphisms with strong evidence of an association with at least one tumor type 
are described below. Findings for each polymorphism are detailed in the Supplementary Results, 
available online. Finally, for five of the 43 meta-analyses (12%) that showed no statistically 
significant association, the cumulative evidence for lack of association with cancer risk was strong. 
 
Associations between TERT locus Polymorphisms and Cancer Risk  
 
rs2736098. Although rs2736098 is a synonymous polymorphism (G>A; Ala305Ala), this TERT 
SNP has been shown to be associated with telomere length, but not with TERT expression (41). On 
the other hand, rs2736098 is in linkage disequilibrium (LD) with rs2853669 (pairwise correlation 
coefficient r
2 
= 0.79) (24), a SNP granted functional relevance (see Supplementary Results, 
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available online). Therefore, rs2736098 may simply be a marker tagging the relevant 
polymorphism.  
Meta-analysis by tumor type revealed a statistically significant association between the 
minor allele rs2736098[A] and both lung (OR = 1.21, 95% CI = 1.15 to 1.27) and bladder cancer 
(OR=1.19, 95% CI = 1.12 to 1.25) (Table 1). According to the Venice criteria, the cumulative 
evidence for the association between rs2736098[A] and the risk of these two tumor types was 
strong. Because the minor allele frequency (MAF) of rs2736098 was 26%, the estimated population 
attributable risk (PAR) for lung and bladder cancer was 6% and 5%, respectively. Meta-analysis of 
available data showed no association between this SNP and either prostate cancer or central nervous 
system (CNS) tumors (Table 2). 
 
rs2736100. SNP rs2736100 is located in intron 2 of TERT and, on the basis of the Evolutionary and 
Sequence Pattern Extraction through Reduced Representation (ESPERR) score (85), is located 
within a putative regulatory region (40). This polymorphism has also been linked to idiopathic 
pulmonary fibrosis, a disease associated with increased risk of developing lung cancer (86). It is 
also the most studied polymorphism of the TERT gene, as it was described in 46 studies enrolling 
74,785 case subjects with 11 tumor types and 115,726 control subjects.  
Thirty two studies reported a statistically significant association between the minor allele 
rs2736100[C] and cancer susceptibility. Notably, for testicular cancer, this allele was associated 
with a decreased disease risk, whereas for all other tumor types it was associated with an increased 
disease risk. Upon meta-analysis, the association between this TERT polymorphism and cancer risk 
was statistically significant for lung, bladder, pancreatic, testis, and CNS tumors (Table 1), but not 
melanoma (data for melanoma is presented in Table 2). Lung cancer was by far the most studied 
tumor type, with 50,917 case subjects and 72,598 control subjects enrolled in 23 studies. The meta-
risk was highly statistically significant (OR =1.19, 95% CI = 1.14 to 1.23), but with a large amount 
of heterogeneity (I
2 
= 77%, P < .001), which made the cumulative evidence for association weak. A 
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stronger association was noted in Asians (OR = 1.26, 95% CI = 1.20 to 1.32) compared with whites 
(OR = 1.11, 95% CI = 1.08 to 1.15; Pheterogeneity for difference between ORs < .001); however, the 
cumulative evidence remained weak for both ancestries because of the small overall association 
among whites and the large heterogeneity (I
2 
= 68%, P < .001) coupled with potential chasing bias 
(Ioannidis and Trikalinos test P = .035) among Asian studies. 
Beacuse data were permissive, we investigated this SNP also in relation with lung cancer subtypes. 
The risk of adenocarcinoma was highest among all subtypes (OR = 1.30, 95% CI = 1.25 to 1.36), 
but again, the cumulative evidence was weak  as a result of lack of replication and large 
heterogeneity (I
2 
= 62%, P = .001). However, when ethnicity was taken into account, the risk 
among whites was highly statistically significant (OR = 1.22, 95% CI = 1.17 to 1.27) and the 
cumulative evidence was strong (estimated PAR = 11%, MAF = 45%). The association of 
rs2736100 with adenocarcinoma was reported to be stronger among never smokers (65), a 
population subset where this is the most common form of lung cancer. Moreover, the estimated 
joint PAR for three polymorphisms including TERT rs2736100, intergenic rs4635969, and 
CLPTM1L rs402710) was 41% (Figure 1). Among Asians, the meta-risk for this tumor subtype was 
higher (OR = 1.35, 95% CI = 1.29 to 1.42, Pheterogeneity <.001) but heterogeneity remained 
statistically significant (I
2 
= 47%, P = .067) and the cumulative evidence for association was 
moderate.  
For squamous cell carcinoma, the meta-risk point estimate was small for rs2736100[C] (OR = 1.06, 
95% CI = 1.01 to 1.12) and the cumulative evidence for association was weak. For small cell lung 
cancer (SCLC), the cumulative evidence for lack of association (OR=1.05, 95% CI = 0.99 to 1.09) 
was strong (Table 2). Other subgroup analyses performed for lung cancer are reported in Table 1. 
rs2736100[C] was statistically significantly associated with reduced risk of testicular germ cell 
carcinoma (TGCC) (OR= 0.75, 95% CI = 0.70 to 0.81), the cumulative evidence for association 
was strong (estimated PAR for the risk allele rs2736100[A] = 22%,risk allele frequency = 55%).  
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For other tumor types, no strong evidence could be demonstrated. For pancreatic cancer, the 
available data were in favor of a small risk increase (OR = 1.12, 95% CI = 1.04 to 1.20) and the 
cumulative evidence was weak. The association of rs2736100[C] with the risk of bladder carcinoma 
was also statistically significant (OR = 1.19, 95% CI = 1.05 to 1.34), but because of the relatively 
low number of subjects enrolled (100<n<1000, n= subjects carrying the minor allele), the 
cumulative evidence was moderate. Finally, the association with risk of CNS tumors was even 
stronger (OR = 1.34, 95% CI = 1.22 to 1.46), but the cumulative evidence for association was weak 
as a result of large heterogeneity (I
2 
= 60%, P = .02). 
 
rs2853676. The association of this TERT intronic polymorphism with risk of cancer was evaluated 
in 18 studies, including 31,481 case subjects (11 tumor types) and 44,122 control subjects. Four 
studies on CNS tumors and one on cutaneous melanoma reported a statistically significantly 
increased risk for carriers of the minor allele (A), whereas one study described a reduced risk for 
TGCC. Meta-analysis by tumor type revealed a strong association between rs2853676[A] and 
increased risk of CNS tumors (OR = 1.26, 95% CI = 1.21 to 1.32), and the cumulative evidence was 
strong (estimated PAR = 7%, MAF = 24%). 
In contrast, the cumulative evidence for lung cancer risk was weak, because of a small meta-risk 
(OR=1.06, 95% CI = 1.01 to 1.10). Finally, no association could be demonstrated for pancreatic 
cancer (OR = 0.93, 95% CI = 0.86 to 1.00) and melanoma (OR = 1.16, 95% CI = 0.81 to 1.66). 
 
rs31489. This intronic SNP of the CLPTM1L gene was chosen because it is located in a DNA 
region in LD with the TERT promoter and the 5'-end of TERT gene (Supplementary Figure 1, 
available online) (9). Nine studies reported statistically significant association between cancer risk 
and the minor allele (A), but with opposite risk directions for lung cancer and skin basal cell 
carcinoma (BCC) (decreased) as compared to pancreatic cancer and TGCC (increased).  
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Meta-analysis by tumor type confirmed that rs31489[A] is associated with an increased risk of 
pancreatic cancer (OR = 1.18, 95% CI = 1.06 to 1.32) and TGCC (OR = 1.28, 95% CI = 1.16 to 
1.41) but is statistically significantly associated with reduced risk of lung cancer (OR = 0.83, 95% 
CI = 0.78 to 0.88) (Table 1). The cumulative evidence for association was strong only for testicular 
cancer (estimated PAR = 11%, MAF = 36%). For the other tumor types no meta-analysis could be 
performed. 
 
rs380286. This SNP is located in an intronic region of CLPTM1L. Two studies reported that 
subjects carrying the minor allele (A) were associated with reduced risk of lung cancer (OR = 0.85, 
95% CI = 0.80 to 0.91), and the cumulative evidence was strong (estimated PAR for risk allele 
rs380286[G] = 13%, major allele frequency = 63%) (note that in this case the "risk" allele coincides 
with the "major" allele). 
 
rs401681. This SNP is located in an intronic region of CLPTM1L. Like rs2736098,  rs401681 was 
reported to be associated with telomere length (but not TERT expression) (41), which supports its 
relevance for telomere biology and potentially cancer development. At present rs401681 is the most 
widely studied TERT locus polymorphism, because it was assessed for cancer risk in 56 series 
enrolling 89,903 case subjects (23 tumor types) and 155,202 control subjects (Supplementary Table 
1, available online). In 29 studies a statistically significant association was observed between the 
minor allele (T) and cancer risk; however, 21 studies described a decreased cancer risk whereas 
eight described an increased risk. 
Meta-analysis by cancer type revealed that rs401681[T] carriers have a modestly increased risk of 
pancreatic carcinoma (OR = 1.14, 95% CI = 1.01 to 1.29) and skin melanoma (OR = 1.12, 95% CI 
= 1.03 to 1.22). Conversely, a modest risk reduction was observed for bladder (OR = 0.89, 95% CI 
= 0.86 to 0.92), lung (OR = 0.87, 95% CI = 0.84 to 0.89) and prostate (OR = 0.92, 95% CI = 0.89 to 
0.95) cancer and skin squamous cell carcinoma (SCC) (OR = 0.92, 95% CI = 0.84 to 0.99). Finally, 
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a more pronounced risk reduction was detected for BCC (OR = 0.82, 95% CI = 0.76 to 0.89). In no 
case was the cumulative evidence strong because of between-study heterogeneity and/or small 
overall association (Table 1).  
For lung cancer, available data also enabled us to perform meta-analysis by ancestry and 
histological subtype. SNP rs401681[T] was associated with statistically significantly reduced risk of 
both adenocarcinoma (OR = 0.87, 95% CI = 0.81 to 0.93) and SCC (OR = 0.85, 95% CI = 0.76 to 
0.96), but not with SCLC (OR = 0.98, 95% CI = 0.90 to 1.07). Nevertheless, the cumulative 
evidence for the first two lung cancer subtypes was weak because of heterogeneity (Table 1). When 
ethnicity was taken into account, a reduced risk of non-small cell lung carcinoma (NSCLC) was 
observed only among Asians (OR = 0.84, 95% CI = 0.79 to 0.90), and the cumulative evidence for 
association was strong (estimated PAR for risk allele rs401681[C] = 13%,major allele frequency = 
60%). 
Finally, no statistically significant relationship was observed for the other tumor types (breast, 
colon, endometrial cancer and TGCC) for which a meta-analysis could be performed; for breast and 
colon carcinomas, the cumulative evidence for lack of association was strong (Table 2). 
 
rs402710. This CLPTM1L intronic SNP is in LD with many other CLPTM1L polymorphisms, 
including the above described rs401681 (see Supplementary Figure 2, available online), but not 
with TERT polymorphisms such as rs2736100, which led some authors to postulate that that the 
5p15.33 locus might host two independent cancer risk SNPs (ie, rs2736100 and rs402710) (29). Ten 
studies reported a statistically significant association between the minor allele (T) and a decreased 
risk of lung, bladder and nasopharyngeal tumors, whereas two other studies described the opposite 
relationship with pancreatic and testicular cancer (Supplementary Table 1, available online).  
Upon meta-analysis, rs402710[T] was associated with reduced risk of both bladder (OR = 0.85, 
95% CI = 0.75 to 0.98) and lung cancer (OR = 0.87, 95% CI = 0.83 to 0.92), but in neither case was 
the cumulative evidence for association strong (Table 1). 
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Available data allowed a meta-analysis of lung cancer histological subtypes for risk assessment. 
Interestingly, rs402710[T] showed a homogeneous and statistically significantly reduced risk of 
both adenocarcinoma (OR = 0.84, 95% CI = 0.80 to 0.89) and SCC (OR = 0.83, 95% CI = 0.77 to 
0.89), the cumulative evidence being strong in both cases (estimated PAR for risk allele 
rs402710[C] = 14%, risk allele frequency = 66%). Finally, no statistically significant association 
was found with the risk of pancreatic cancer (OR = 1.14, 95% CI = 0.98 to 1.32). 
 
rs4635969. Considering the minor allele (A) of this TERT/CLPTM1L intergenic SNP, available 
studies reported opposing but statistically significant findings for lung cancer (decreased risk) and 
both pancreatic cancer and TGCC (increased risk). Meta-analysis by tumor type confirmed an 
association between rs4635969[A] and reduced risk of lung cancer (OR = 0.86, 95% CI = 0.82 to 
0.90), although the cumulative evidence was weak because of a small overall association. As also 
reported for rs2736100, the reduced risk was more pronounced in lung adenocarcinoma (OR = 0.81, 
95% CI = 0.75 to 0.88), for which the cumulative evidence for association could be classified as 
strong (estimated PAR for risk allele rs4635969[G] = 23%, major allele frequency = 80%).  
Among rs4635969[A] carriers, the risk was statistically significantly increased for pancreatic (OR = 
1.22, 95% CI = 1.14 to 1.32) and testicular (OR = 1.61, 95% CI = 1.46 to 1.76) carcinomas.. In 
these two cancers, the overall evidence for association was strong, the estimated PAR being 5% and 
14%, respectively. Of note, the meta-risk for TGCC associated with this SNP was the strongest 
association found in the present meta-analysis. 
 
rs465498. All four studies evaluating this intronic CLPTM1L SNP found a statistically significantly 
reduced cancer risk in people carrying the minor allele (G). Pooling the summary data confirmed 
this association (OR = 0.79, 95% CI = 0.74 to 0.84), although the cumulative evidence for 
association appeared moderate as a result of heterogeneity (I
2 
= 49%, P = .12). Restricting the 
analysis to the Asian ancestry by pooling data from three series (a GWAS with one discovery and 
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two independent replication phases) resulted in a homogeneous (I
2 
= 0%, P = .76) and statistically 
significant association with reduced risk of cancer (OR = 0.76, 95% CI = 0.72 to 0.81), which was 
statistically significantly lower (Pheterogeneity = .021) than that reported in the study restricted to white 
subjects (OR = 0.85, 95% CI = 0.79 to 0.92) and the cumulative evidence was strong (estimated 
PAR for risk allele rs465498[A] among Asians = 36%, major allele frequency among Asians = 
83%). 
 
rs467095. The three studies reporting on the allele distribution of this intronic CLPTM1L 
polymorphism described a reduced cancer risk in people carrying the minor allele (C). Pooling the 
summary data confirmed the association of rs467095[C] with reduced cancer risk (OR = 0.83, 95% 
CI = 0.78 to 0.85), and the cumulative evidence for association was strong (estimated PAR for the 
risk allele rs467095[T] = 17%, major allele frequency ≈ 72%) 
 
MNS16a. This variable tandem repeat polymorphism (short [S] vs long [L] polymorphism) is 
located downstream of the TERT gene and was reported to affect promoter activity in lung cancer 
cell lines (21), although the functional importance of the antisense transcript activity is unclear. 
Two studies on CNS tumors and one on breast cancer reported that the minor allele (S) was 
associated with an increased risk of disease development.  
The meta-analysis showed that MNS16a[S] is associated with a homogeneously reported (I
2 
= 8%, 
P = .30) statistically significantly increased risk of CNS tumors (OR = 1.20, 95% CI = 1.07 to 1.33; 
I
2 
= 8%, P = .30), but not breast (OR = 1.20, 95% CI = 0.84 to 1.71) or lung (OR = 0.99, 95% CI = 
0.62 to 1.60) carcinomas. The cumulative evidence for association between MNS16a[S] and CNS 
tumors was strong (estimated PAR = 7%, MAF = 34%). 
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Discussion 
 
This work, to our knowledge, is the first synopsis of the literature on the role of polymorphisms at 
the TERT locus (5p15.33) in cancer predisposition. Upon systematic review and meta-analysis of 
the data from 85 molecular epidemiology studies, enrolling almost half a million people tested for 
one or more of 67 polymorphisms, which generated 494 allelic contrasts, we found that 22 
polymorphisms were associated with the risk of developing one or more types of cancer, but only 
11 showed strong cumulative evidence for association, according to the Venice criteria.  
The risks were relatively low, with ORs for risk alleles ranging between 1.05 and 1.61 and those for 
protective alleles between 0.92 and 0.75. Accordingly, PAR, which takes into account both 
magnitude of the risk and risk allele frequency in the general population, varied from 4% to 36%. 
Although these figures might suggest at first glance that the TERT locus does not play a major role 
in cancer susceptibility, a couple of considerations should be made. First, it is widely recognized 
that single common polymorphisms are generally associated with low risks (ie, OR<1.5) (20), 
which calls for considering the effect of combinations of multiple polymorphisms. A few studies 
(29,37,54,63) addressed this issue by assessing the effect of TERT locus haplotypes on cancer risk: 
however, the haplotypes considered by different authors are heterogeneous and thus no meta-
analysis could be performed. Other investigators have verified that some polymorphisms (eg, 
rs2736100 and rs2736098) carry a risk independently of others [eg, rs402710 (29), rs4635969 (40), 
and rs401681 (41)] using multivariable logistic regression analysis, but unfortunately the models 
(ie, the combination of included covariates) are not equal and thus their results cannot be merged. 
Nevertheless, to provide readers with an idea of the potential predictive value of multiple 
polymorphisms, we considered three unrelated (based on pairwise correlation coefficient r
2
 <0.1 
and multivariable analysis) polymorphisms (ie TERT rs2736100, intergenic rs4635969, and 
CLPTM1L rs402710) with a strong cumulative evidence for association with lung adenocarcinoma 
and we found that the estimated joint PAR defined by these polymorphisms is 41% (see Figure 1), 
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which corresponds to a 0.5% attributable community risk (considering a 1.2% lifetime risk of lung 
adenocarcinoma). Although we could calculate only a per-allele PAR (that is, only the co-dominant 
model was tested), this result highlights the pivotal role that TERT locus polymorphisms play in the 
determination of the most frequent histological subtype of lung cancer, and exemplifies the 
importance of further investigation on the 5p15.33 region with regard to cancer predisposition in 
general. 
Another key point is that the TERT gene alone (without considering the rest of the TERT locus) has 
more than 500 known SNPs, whereas thus far the relationship with cancer risk has been investigated 
only for 67 SNPs, which is a minority of these polymorphisms. It should also be remembered that 
only 24 tumor types were investigated and that on average each polymorphism was tested for about 
three tumor types (range = 1-23)(see the heat-map in Supplementary Figure 3, available online). 
Furthermore, as we reported above, for many polymorphisms some evidence of association with 
cancer risk already exists, although more data are necessary to conclusively define their role (see 
Table 1 for polymorphisms with moderate or weak cumulative evidence; and Supplementary Table 
1, available online for polymorphisms with statistically significant association in a single study). In 
contrast, only for a minority of the polymorphisms investigated to date (5 of 67 [7%]) the available 
results are compatible with no relevance for the susceptibility of three tumor types (see Table 2 for 
strong cumulative evidence), which does not rule out that these SNPs might be associated with the 
risk of other tumor types. Therefore, this synopsis, which strongly supports the relevance of the 
TERT locus to define the genetic architecture of cancer predisposition, also underscores that much 
work remains to be done before we can entirely appreciate the importance of this DNA region in 
cancer development.  
 
The 5p15.33 locus is characterized by a 62 Kb linkage disequilibrium (LD) block including the 5'-
end of TERT, its promoter and the entire gene CLPTM1L (Supplementary Figure 2, available 
online); consequently, there are two genes that can be involved in the tumor promoting effects 
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epidemiologically linked to the above described polymorphisms. Certainly TERT is the more 
appealing candidate because of its well-known role in telomere and tumor biology. However, we 
must underscore the discrepancy between the epidemiological findings associating TERT 
polymorphisms to cancer risk and the relatively scarce (29) and sometime conflicting evidence 
(59,87) associating the same polymorphisms to telomere length, a key aspect linking these 
chromosomal structures to cancer biology. In light of these controversies, more work is warranted 
to elucidate the molecular mechanisms possibly responsible for these epidemiological observations. 
For example, rs2736100 and other SNP in the locus are close to mutations known to alter 
telomerase activity (88). The complete sequencing of this locus in cancer patients will help 
investigators to fully elucidate the relationship between the TERT locus polymorphisms and cancer 
risk. 
For the other gene in this region, CLPTM1L  might be relevant not only because is in LD with 
TERT but also in the light of its own biological activity; its product (cleft lip and palate 
transmembrane protein 1-like protein) is known to induce cisplatin resistance in ovarian cancer cells 
(the CLPTM1L product is also called cisplatin resistance related protein [CRR9]) (89). Moreover, 
its SNP rs402710 has been recently associated with higher levels of bulky aromatic and 
hydrophobic DNA adducts (47), a typical product of lung cancer carcinogens such as polycyclic 
aromatic hydrocarbons and tobacco-specific nitrosamines.   
Considering that, for both genes, virtually all polymorphisms have no effect on protein sequence 
(all polymorphisms for which a meta-analysis could be performed were either intronic or exonic-
synonymous or intergenic) (Supplementary Table 1, available online), the association of these 
polymorphisms with cancer susceptibility might derive from either their LD with still undetected 
functional polymorphisms (ie, exonic non-synonymous) or from their effect on protein expression 
(although the latter hypothesis does not appear to be supported by the evidence collected thus far, as 
mentioned above). Overall, the findings collected in this synopsis, which are virtually always based 
on tagging SNP, might tip the balance in favor of gene-centric strategies, that is, studies based on 
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the use of polymorphisms known to affect protein sequence. However, some investigators have 
recently reported no meaningful results adopting this approach, and have hypothesized that natural 
selection has rendered non-synonymous alleles so rare (ie, MAF<5%) that sample sizes greater than 
those utilized for common alleles should be used to detect statistically significant associations (90). 
Remembering that in this synopsis, where virtually all studies regarded polymorphisms with MAF 
greater than 5%, the mean sample size is approximately 6,000 subjects, the practical difficulty of 
carrying out gene-centric research is self-evident. 
 
An intriguing finding of our work is that the association between a given polymorphism and cancer 
risk can be very specific not only in terms of ethnicity/histology but also in terms of effect direction 
(Table 1). Indeed we found that some 5p15.33 locus polymorphisms correlate (with strong 
evidence) with cancer risk only in whites (eg, rs2736100 in lung adenocarcinoma) or Asians (eg, 
rs402710 in lung cancer), and that others predispose to a specific histological subtype of cancer (eg, 
rs2736100 and rs4027100 in lung adenocarcinoma). More surprisingly, the same polymorphism 
(eg, rs2736100; rs401681) can result in an increased risk for some cancer types (eg, lung cancer; 
BCC) and a reduced risk for others (eg, TGCC; melanoma). In the case of melanoma and BCC, this 
finding, apparently contradictory, is in line with the opposite effect that telomere shortening (which 
is accelerated in rs401681[C] carriers (41)) can have on the two tumor types (91,92). On the other 
hand, our observation lends support to a double hypothesis: 1) no common molecular pathway leads 
to the development of all cancer types, and 2) some pathways favoring the development of some 
tumor types might even oppose the genesis of others. Some clinical epidemiology evidence is in the 
same direction: for example, women taking tamoxifen (a drug interfering with the estrogen receptor 
pathway) are at lower risk of breast but at higher risk of endometrial cancer; and people affected 
with skin melanoma (and thus with a genetic background predisposing to this tumor) are at higher 
risk of secondary melanoma but also at lower risk of gastrointestinal and lung tumors (93). Though 
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appealing, this hypothesis clearly warrants further investigation to be validated and thus to be 
exploitable on the clinical ground. 
 
Finally, the limitations of this synopsis must be addressed. For example, although an exhaustive 
literature search was performed, it is possible that some publications were overlooked; moreover, 
not all the GWAS authors we contacted agreed to provide their data; finally, only for a minority of 
studies genotype data (either as raw or summary data) were provided, which enabled us to test only 
the co-dominant model (per-allele risk analysis). We hope that this large collection of data on TERT 
locus polymorphisms and cancer risk will prompt investigators to share their knowledge in this 
field, also exploiting the dedicated online data repository above mentioned (available at 
http://www.mmmp.org) (13). Furthermore, we used allele counts and crude estimates of effect, 
rather than association estimates adjusted by other polymorphisms, genes or even environmental 
factors. As discussed above, for interaction between polymorphisms, the models used in single 
eligible studies differ in most cases and were therefore unsuitable for pooling. Lung cancer was the 
only tumor type for which investigators often reported data adjustment for smoking, the most 
common environmental risk factor. In this case, the impact of TERT locus polymorphisms was 
generally unaffected by smoking (80), which strengthens the findings of our meta-analysis, 
although it does not rule out other confounding factors [eg, chronic obstructive pulmonary disease 
(84)]. Again, even for lung cancer the adjustment for smoking was reported in different ways (eg, as 
a single OR adjusted by including smoking behavior in a logistic regression model or by providing 
multiple OR obtained separately in smoking and non-smoking subjects), which precluded any 
meaningful pooling of summary data.    
For gene-gene interactions, it should be remembered that tens of genes are currently known to 
contribute to telomere biology (94) and thus may contribute to modulate cancer susceptibility. 
However, to date only a few authors investigated the relationship between polymorphisms of 
telomere-related genes (other than TERT) and predisposition to few tumor types 
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(24,28,37,45,60,62,75), and because the available results are sparse (different tumor types), no data 
merging could be performed, which calls for further research in this field. 
Multiple testing is another possible concern. We performed a total of 118 meta-analyses (including 
ethnicity-specific and cancer subtype-specific analyses): considering a Bonferroni adjustment, the P 
value threshold for statistical significance would be .0004, which would reduce statistically 
significant associations from 75 to 47 (Table 1, P values tagged with symbols). Nevertheless, it 
should be noted that this P value is overly conservative because many tests were performed in 
independent data sets. Furthermore, lowering the alpha level of significance increases the possibility 
of type II error (ie, reduces statistical power). More importantly, polymorphisms statistically 
significantly associated with cancer risk were graded according to the Venice criteria, providing 
evidence over and above statistical P values. 
 
In conclusion, this synopsis demonstrates that genetic variation in the TERT locus is likely to play a 
relevant role in cancer development. However, it also underscores that much work still needs to be 
done to clarify the molecular mechanisms underlying this epidemiological observation and to define 
the interactions of this evidence with the other pieces of the cancer predisposition puzzle.  
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Figure  legend 
 
Figure 1. Flow chart for the estimation of the joint risk of lung adenocarcinoma in the general 
population attributable to three TERT locus polymorphisms. Top panel. A forest plot depicting the 
meta-analysis of the studies that contributed to define the association between the minor alleles of 
three single nucleotide polymorphisms (SNPs) and the risk of developing lung adenocarcinoma. 
Open squares represent odds ratios (OR) of single studies (the width of each square is proportional 
to the weight of the corresponding study; the horizontal line represents the 95% confidence interval 
[CI] of the study OR); solid black diamonds represent summary OR for each SNP (the width of 
each diamond is proportional to the 95% CI of the corresponding summary OR). Bottom left 
panel.Only SNP showing strong cumulative evidence for association with lung adenocarcinoma 
were selected. Cumulative evidence was assessed as per the Venice criteria (see text for more 
details). OR refer to risk alleles (alleles associated with increased cancer risk). Bottom right panel. 
The joint PAR (population attributable risk) represents the proportion of lung adenocarcinoma cases 
estimated to be attributable to the three SNP showing strong cumulative evidence of association; it 
depends on both the magnitude of the association (OR) and the risk allele frequency in the general 
population.  
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Table 1. TERT locus polymorphisms for which the meta-analysis demonstrated a statistically significant association with cancer risk * 
POLYMORPHISM DATA STUDY FEATURES META-ANALYSIS FINDINGS 
Polymorphism 
ID 
Gene Allele Race or ethnicity No. of 
studies  
Case 
subjects, 
No. 
Control 
subjects, 
No. 
Cancer OR (95% CI) P for  
Z-test 
†
 
I2 (%) P for  
Q test 
†
 
Level of 
evidence 
‡
 
rs13167280 TERT T White 2 1581 1889 Bladder 1.23 (1.07 to 1.42) .004 0 .45 BAA/moderate 
rs1801075 Intergenic C Miscellany § 4 3552 4340 Lung (miscellany ║) 0.88 (0.80 to 0.96) .006 0 .49 AAC/weak 
rs2242652 TERT T White 4 33600 32419 Prostate 0.82 (0.76 to 0.89) 9.0E-07¶ 61 .05 ACA/weak 
rs2735845 Intergenic G Miscellany 3 7213 7523 Lung (miscellany) 1.11 (1.05 to 1.17) 2.3E-04¶ 0 .39 AAC/weak 
rs2736098 TERT A Miscellany 3 4617 10134 Bladder 1.19 (1.12 to 1.25) 8.6E-10¶ 0 .87 AAA/strong 
rs2736098 TERT A Miscellany 4 6949 12492 Lung (miscellany) 1.21 (1.15 to 1.27) 2.2E-13¶ 0 .99 AAA/strong 
rs2736100 TERT C Miscellany 2 970 1072 Bladder 1.19 (1.05 to 1.34) .007 0 .64 BAA/moderate 
rs2736100 TERT C Miscellany 6 6871 12449 CNS 1.34 (1.23 to 1.46) 4.4E-11¶ 60 .029 ACA/weak 
rs2736100 TERT C White 5 5918 11413 CNS 1.35 (1.22 to 1.50) 1.2E-08¶ 65 .021 ACA/weak 
rs2736100 TERT C Miscellany 23 50917 72598 Lung (miscellany) 1.19 (1.14 to 1.23) <1.0E-16¶ 77 2.9E-11 ACA/weak 
rs2736100 TERT C White 11 30650 41248 Lung (miscellany) 1.11 (1.08 to 1.15) 1.1E-12¶ 35 .12 AAC/weak 
rs2736100 TERT C Asian 12 20267 31350 Lung (miscellany) 1.26 (1.20 to 1.32) <1.0E-16¶ 68 3.5E-04 ACB/weak 
rs2736100 TERT C Miscellany 14 22045 68197 Lung (adenocarcinoma) 1.30 (1.25 to 1.36) <1.0E-16¶ 62 .001 ACB/weak 
rs2736100 TERT C Miscellany 13 11645 57483 Lung (squamous) 1.06 (1.01 to 1.12) .017 54 .011 ACC/weak 
rs2736100 TERT C Miscellany 29 35509 61787 Lung (NSCLC) 1.19 (1.14 to 1.25) 3.3E-14¶ 80 1.1E-16 ACA/weak 
rs2736100 TERT C White 6 9540 37840 Lung (adenocarcinoma) 1.22 (1.17 to 1.27) <1.0E-16¶ 0 .42 AAA/strong 
rs2736100 TERT C Asian 8 12505 30357 Lung (adenocarcinoma) 1.35 (1.29 to 1.42) <1.0E-16¶ 47 .06 ABA/moderate 
rs2736100 TERT C White 6 6626 37840 Lung (squamous) 1.05 (1.00 to 1.10) .043 30 .21 ABA/moderate 
rs2736100 TERT C White 13 16572 37840 Lung (NSCLC) 1.15 (1.09 to 1.22) 1.2E-06¶ 73 9.2E-06 ACA/weak 
rs2736100 TERT C Asian 16 18937 23947 Lung (NSCLC) 1.24 (1.16 to 1.31) 2.4E-12¶ 74 5.2E-07 ACA/weak 
rs2736100 TERT C White 2 3851 3934 Pancreas 1.12 (1.04 to 1.20) .001 0 .77 AAC/weak 
rs2736100 TERT C White 3 1959 8679 Testis 0.75 (0.70 to 0.81) 4.4E-16¶ 0 .62 AAA/strong 
rs2853668 Intergenic T White 2 11067 12517 Colon 0.90 (0.82 to 0.99) .034 72 .05 ACC/weak 
rs2853668 Intergenic T Miscellany 2 5531 6284 Lung (miscellany) 1.09 (1.02 to 1.15) .009 0 .66 AAC/weak 
rs2853668 Intergenic T White 2 3851 3934 Pancreas 0.92 (0.85 to 0.99) .046 0 .68 AAC/weak 
rs2853676 TERT A Miscellany 4 6010 8313 CNS 1.26 (1.21 to 1.32) <1.0E-16¶ 0 .58 AAA/strong 
rs2853676 TERT A Miscellany 3 11205 11957 Lung (miscellany) 1.06 (1.01 to 1.10) .008 0 .79 AAC/weak 
rs31489 CLPTM1L A Miscellany 6 13929 16047 Lung (miscellany) 0.83 (0.78 to 0.88) 4.2E-09¶ 55 .05 ACA/weak 
rs31489 CLPTM1L A White 4 10594 11070 Lung (miscellany) 0.84 (0.78 to 0.90) 1.5E-06¶ 58 .07 ACA/weak 
rs31489 CLPTM1L A Asian 2 3335 4977 Lung (miscellany) 0.80 (0.70 to 0.91) .001 44 .18 ABA/moderate 
rs31489 CLPTM1L A White 2 3851 3934 Pancreas 1.18 (1.06 to 1.32) .003 70 .06 ACA/weak 
rs31489 CLPTM1L A White 2 1191 5805 Testis 1.28 (1.16 to 1.41) 1.4E-06¶ 18 .27 AAA/strong 
rs380286 CLPTM1L A Miscellany 2 5529 6289 Lung (miscellany) 0.85 (0.80 to 0.91) 5.8E-07¶ 0 .84 AAA/strong 
rs401681 CLPTM1L T Miscellany 4 8645 41188 Bladder 0.89 (0.86 to 0.92) 9.2E-11¶ 0 .81 AAC/weak 
rs401681 CLPTM1L T White 3 4152 32824 Pancreas 1.14 (1.01 to 1.29) .037 77 .013 ACC/weak 
rs401681 CLPTM1L T White 3 11235 74276 Prostate 0.92 (0.89 to 0.95) 3.8E-06¶ 0 .63 AAC/weak 
rs401681 CLPTM1L T White 3 3941 32808 BCC (skin) 0.82 (0.76 to 0.89) 4.2E-06¶ 49 .14 ABA/moderate 
rs401681 CLPTM1L T White 5 8012 38925 Melanoma (skin) 1.12 (1.03 to 1.22) .006 72 .007 ACC/weak 
rs401681 CLPTM1L T White 3 1478 30525 SCC (skin) 0.92 (0.84 to 0.99) .046 0 .57 AAC/weak 
rs401681 CLPTM1L T Miscellany 12 25674 58027 Lung (miscellany) 0.87 (0.84 to 0.90) <1.0E-16¶ 33 .13 ABA/moderate 
rs401681 CLPTM1L T White 8 18641 48866 Lung (miscellany) 0.87 (0.84 to 0.90) 3.5E-14¶ 34 .15 ABA/moderate 
rs401681 CLPTM1L T Asian 4 7033 9161 Lung (miscellany) 0.86 (0.81 to 0.93) 2.9E-05¶ 46 .13 ABA/moderate 
rs401681 CLPTM1L T Miscellany 6 5900 43343 Lung (adenocarcinoma) 0.87 (0.81 to 0.93) 4.3E-05¶ 52 .06 ACA/weak 
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rs401681 CLPTM1L T Miscellany 5 5319 40522 Lung (squamous) 0.85 (0.76 to 0.96) .010 72 .006 ACA/weak 
rs401681 CLPTM1L T Miscellany 12 11852 53575 Lung (NSCLC) 0.86 (0.82 to 0.91) 1.9E-07¶ 56 .01 ACA/weak 
rs401681 CLPTM1L T White 3 2231 37259 Lung (adenocarcinoma) 0.90 (0.82 to 0.98) .019 45 .16 ABC/weak 
rs401681 CLPTM1L T Asian 3 3669 6084 Lung (adenocarcinoma) 0.84 (0.76 to 0.93) 7.5E-04 57 .10 ACA/weak 
rs401681 CLPTM1L T Asian 2 736 4184 Lung (squamous) 0.85 (0.75 to 0.96) .010 0 .95 BAA/moderate 
rs401681 CLPTM1L T White 7 7447 43307 Lung (NSCLC) 0.87 (0.80 to 0.95) .001 67 .01 ACA/weak 
rs401681 CLPTM1L T Asian 5 4405 10268 Lung (NSCLC) 0.84 (0.79 to 0.90) 1.5E-07¶ 14 .32 AAA/strong 
rs402710 CLPTM1L T Miscellany 2 974 1055 Bladder 0.85 (0.75 to 0.98) .022 0 .36 BAA/moderate 
rs402710 CLPTM1L T Miscellany 12 31364 35462 Lung (miscellany) 0.88 (0.83 to 0.92) 8.1E-07¶ 65 .002 ACC/weak 
rs402710 CLPTM1L T White 8 24471 26161 Lung (miscellany) 0.89 (0.84 to 0.94) 5.2E-05¶ 69 .004 ACC/weak 
rs402710 CLPTM1L T Asian 4 6893 9301 Lung (miscellany) 0.87 (0.82 to 0.91) 8.2E-08¶ 9 .35 AAA/strong 
rs402710 CLPTM1L T Miscellany 3 4929 15011 Lung (adenocarcinoma) 0.84 (0.80 to 0.89) 5.9E-10¶ 0 .42 AAA/strong 
rs402710 CLPTM1L T Miscellany 3 2461 15011 Lung (squamous) 0.83 (0.77 to 0.89) 4.1E-07¶ 0 .94 AAA/strong 
rs402710 CLPTM1L T Miscellany 8 8945 31783 Lung (NSCLC) 0.84 (0.81 to 0.88) 2.2E-16¶ 0 .78 AAA/strong 
rs4246742 TERT T Miscellany 2 5528 6274 Lung (miscellany) 1.08 (1.01 to 1.15) .018 0 .83 AAC/weak 
rs451360 CLPTM1L A Miscellany 3 6983 8058 Lung (miscellany) 0.80 (0.70 to 0.92) .001 70 .035 ACB/weak 
rs451360 CLPTM1L A White 2 4652 4981 Lung (miscellany) 0.85 (0.76 to 0.95) .004 48 .16 ABA/moderate 
rs452384 CLPTM1L C Miscellany 2 5302 6823 Lung (miscellany) 0.82 (0.74 to 0.90) 7.4E-05¶ 52 .15 ACA/weak 
rs452932 CLPTM1L C Miscellany 2 5302 6823 Lung (miscellany) 0.82 (0.74 to 0.90) 7.4E-05¶ 52 .15 ACA/weak 
rs4635969 Intergenic A Miscellany 4 12893 13126 Lung (miscellany) 0.86 (0.82 to 0.90) 8.1E-10¶ 8 .35 AAA/strong 
rs4635969 Intergenic A Miscellany 2 3674 8230 Lung (adenocarcinoma) 0.81 (0.75 to 0.88) 1.2E-06¶ 0 .87 AAA/strong 
rs4635969 Intergenic A Miscellany 2 1594 8230 Lung (squamous) 0.87 (0.78 to 0.97) .010 0 .45 AAA/strong 
rs4635969 Intergenic A Miscellany 4 5268 8230 Lung (NSCLC) 0.83 (0.78 to 0.89) 6.0E-08¶ 0 .69 AAA/strong 
rs4635969 Intergenic A White 2 3851 3934 Pancreas 1.22 (1.14 to 1.32) 1.1E-07¶ 0 .86 AAA/strong 
rs4635969 Intergenic A White 3 1729 9079 Testis 1.61 (1.47 to 1.75) <1.0E-16¶ 0 .77 AAA/strong 
rs465498 CLPTM1L G Miscellany 4 11579 13190 Lung (miscellany) 0.79 (0.74 to 0.84) 2.6E-12¶ 49 .12 ABA/moderate 
rs465498 CLPTM1L G Asian 3 8608 9444 Lung (miscellany) 0.76 (0.72 to 0.81) <1.0E-16¶ 0 .76 AAA/strong 
rs467095 CLPTM1L C Miscellany 3 7739 9271 Lung (miscellany) 0.83 (0.78 to 0.87) 3.9E-11¶ 0 .37 AAA/strong 
rs4975615 Intergenic G Miscellany 3 6983 8058 Lung (miscellany) 0.81 (0.76 to 0.87) 2.7E-10¶ 26 .26 ABA/moderate 
rs4975616 Intergenic G Miscellany 7 12743 14130 Lung (miscellany) 0.83 (0.79 to 0.88) 1.1E-11¶ 41 .12 ABA/moderate 
rs4975616 Intergenic G White 2 3851 3934 Pancreas 0.85 (0.78 to 0.94) .001 57 .13 ACA/weak 
rs4975616 Intergenic G White 2 1328 5861 Testis 1.20 (1.03 to 1.40) .016 55 .13 ACA/weak 
MNS16a TERT S White 2 1764 1664 CNS 1.19 (1.07 to 1.33) .001 8 .30 AAA/strong 
* Telomerase reverse transcriptase (TERT) locus includes TERT and cleft lip and palate transmembrane 1-like (CLPTM1L) genes. OR = odds ratio; CI = confidence interval; BCC = basal cell 
carcinoma; SCC =squamous cell carcinoma; CNS =central nervous system; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer.  
† All P values calculated by Z-test or Q test were two-sided.  
‡ A,B, and C represent the Venice criteria grades for amount of evidence, replication of association and protection from bias, which ultimately define the level of cumulative evidence (strong, 
moderate, weak). 
§ Mix of different races. 
║Mix of different histological subtypes. 
¶ Statistically significant P values after Bonferroni adjustment for multiple testing. 
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Table 2. TERT locus polymorphisms for which the meta-analysis demonstrated no nominally statistically significant association with cancer risk *  
POLYMORPHISM DATA STUDY CHARACTERISTIC META-ANALYSIS FINDINGS 
Polymorphism 
ID 
Gene Allele Race or 
ethnicity 
No. of 
studies 
Case 
Subjects, 
No. 
Control 
subjects, 
No. 
Cancer type OR (95% CI) P for Z-
test 
†
 
I2, % P for Q 
test 
†
 
Level of 
evidence
 ‡
 
rs10073340 CLPTM1L T White 2 3851 3934 Pancreas 0.95 (0.73 to 1.23) .68 89 .002 weak 
rs13167280 TERT T White 2 2989 3360 Breast 1.02 (0.91 to 1.16) .69 0 .82 weak 
rs2075786 TERT T White 2 2953 3333 Breast 1.01 (0.94 to 1.09) .77 0 .45 weak 
rs2075786 TERT T Miscellany § 4 3134 3130 Lung (miscellany ║) 1.31 (0.98 to 1.75) .06 74 .01 weak 
rs2075786 TERT T Asian/Black 3 2770 2750 Lung (miscellany) 1.45 (0.88 to 2.37) .14 82 .004 weak 
rs2242652 TERT T Miscellany 2 4619 5360 Lung (miscellany) 1.06 (0.94 to 1.19) .36 48 .17 weak 
rs2735940 Intergenic T White 2 1453 2584 Bladder 0.96 (0.87 to 1.05) .37 0 .77 weak 
rs2735940 Intergenic T White 2 3180 3405 Breast 0.99 (0.93 to 1.07) .92 0 .99 weak 
rs2735940 Intergenic T Miscellany 6 3682 4099 Lung (miscellany) 1.08 (0.95 to 1.23) .25 59 .032 weak 
rs2735940 Intergenic T White 3 2746 3166 Lung (miscellany) 1.04 (0.89 to 1.22) .62 65 .06 weak 
rs2735940 Intergenic T Asian/Black 3 936 933 Lung (miscellany) 1.20 (0.84 to 1.72) .32 64 .06 weak 
rs2736098 TERT A Miscellany 2 1102 1182 CNS 1.07 (0.77 to 1.48) .69 56 .13 weak 
rs2736098 TERT A White 2 8708 48804 Prostate 1.10 (1.00 to 1.20) .05 83 .015 weak 
rs2736100 TERT C Miscellany 9 6002 50492 Lung (SCLC) 1.05 (0.99 to 1.10) .06 13 .33 strong 
rs2736100 TERT C Asian 7 5019 19643 Lung (squamous) 1.08 (0.98 to 1.18) .11 53 .05 weak 
rs2736100 TERT C White 2 3341 4533 Melanoma (skin) 1.03 (0.95 to 1.11) .46 0 .62 weak 
rs2736109 Intergenic A White 2 2967 3331 Breast 0.96 (0.75 to 1.23) .76 90 .001 weak 
rs2736122 TERT T Miscellany 3 11215 11908 Lung (miscellany) 0.97 (0.92 to 1.01) .19 0 .80 strong 
rs2736122 TERT T Miscellany 2 3851 3934 Pancreas 1.00 (0.93 to 1.08) .94 0 .37 weak 
rs2853669 Intergenic C White 3 3787 3824 Breast 1.02 (0.91 to 1.14) .76 52 .12 weak 
rs2853676 TERT A Miscellany 2 3851 3934 Pancreas 0.93 (0.86 to 1.00) .06 0 .40 weak 
rs2853676 TERT A White 2 3349 4542 Melanoma (skin) 1.16 (0.81 to 1.66) .42 88 .003 weak 
rs2853677 TERT C White 2 2963 3340 Breast 1.03 (0.96 to 1.10) .43 0 .53 weak 
rs2853677 TERT C Miscellany 4 2252 1809 Lung (miscellany) 1.31 (0.97 to 1.75) .073 63 .046 weak 
rs2853677 TERT C White 2 2045 1615 Lung (miscellany) 1.34 (0.88 to 2.06) .17 76 .04 weak 
rs2853677 TERT C Asian/Black 2 207 194 Lung (miscellany) 1.38 (0.62 to 3.05) .43 74 .05 weak 
rs2853690 TERT T White 2 2983 3340 Breast 0.98 (0.89 to 1.08) .74 0 .60 weak 
rs2853690 TERT T Miscellany 2 459 483 Lung (NSCLC) 0.89 (0.63 to 1.25) .51 0 .75 weak 
rs31484 CLPTM1L T Miscellany 2 5302 6823 Lung (miscellany) 0.95 (0.61 to 1.48) .83 97 2.1E-10 weak 
rs401681 CLPTM1L T White 3 10254 36832 Breast 1.01 (0.97 to 1.05) .65 0 .47 strong 
rs401681 CLPTM1L T White 4 5124 33326 Colon 1.05 (0.98 to 1.12) .15 36 .20 strong 
rs401681 CLPTM1L T White 2 1095 30463 Endometrium 0.94 (0.73 to 1.21) .61 86 .007 weak 
rs401681 CLPTM1L T White 2 1328 5861 Testis 1.18 (0.99 to 1.40) .06 67 .08 weak 
rs401681 CLPTM1L T Miscellany 3 1573 37295 Lung (SCLC) 0.98 (0.90 to 1.07) .66 9 .33 weak 
rs401681 CLPTM1L T White 3 4583 36338 Lung (squamous) 0.85 (0.70 to 1.04) .11 86 .001 weak 
rs402710 CLPTM1L T White 2 3851 3934 Pancreas 1.14 (0.98 to 1.33) .10 83 .014 weak 
rs466502 CLPTM1L G Miscellany 2 5302 6823 Lung (miscellany) 0.96 (0.65 to 1.42) .84 97 8.2E-09 weak 
rs4975605 TERT A Miscellany 3 11177 11835 Lung (miscellany) 0.96 (0.92 to 1.00) .06 0 .94 strong 
rs4975605 TERT A White 2 3851 3934 Pancreas 1.03 (0.96 to 1.10) .39 0 .64 weak 
rs7712562 Intergenic C White 2 2965 3341 Breast 1.00 (0.82 to 1.21) .97 70 .06 weak 
rs7727912 CLPTM1L T White 2 4652 4981 Lung (miscellany) 1.01 (0.74 to 1.39) .94 85 .01 weak 
MNS16a TERT S Miscellany 2 2058 2194 Breast 1.20 (0.84 to 1.71) .32 85 .01 weak 
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MNS16a TERT S Miscellany 2 990 1015 Lung (NSCLC) 0.99 (0.62 to 1.60) .98 61 .11 weak 
 
* Telomerase reverse transcriptase (TERT) locus includes TERT and cleft lip and palate transmembrane 1-like (CLPTM1L) genes. OR: odds ratio; CI: confidence interval; CNS: central nervous 
system; NSCLC: non small cell lung cancer; SCLC: small cell lung cancer. 
† All P values calculated by Z-test or Q test were two-sided.  
‡ Levels of cumulative evidence (strong vs weak) were defined according to statistical power and between-study heterogeneity.  
§ Mix of different races. 
║Mix of different histological subtypes. 
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CONTEXT AND CAVEATS  
 
Prior knowledge 
Previous studies have provided abundant evidence that polymorphisms in the telomerase reverse 
transcriptase (TERT) gene are associated with cancer development, but a comprehensive synopsis is 
currently not available. 
Study design 
Publications in English were searched for associations between TERT locus polymorphisms and 
risk of cancer. A systematic review and meta-analysis of literature was conducted to assess the 
cumulative evidence for associations according to the Venice criteria. Because TERT locus also 
includes the cleft lip and palate transmembrane 1-like (CLPTM1L) gene, CLPTM1L polymorphisms 
were also analyzed. 
Contribution 
Eighty-five studies contributed data for 67 TERT locus polymorphisms from 24 tumor types for a 
total of 221 unique combinations of polymorphisms and cancer types. Meta-analysis showed that 22 
polymorphisms were associated with risk of at least one cancer type. Cumulative evidence for 
associations with at least one tumor type was strong for 11 polymorphisms.  
Implications 
This synopsis confirms that genetic variation in the TERT locus can modulate cancer risk. 
Limitations 
Some publications may have been overlooked. For some polymorphisms and tumors, data were 
insufficient for pooling. 
 
 
